The new (version 9) American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) staging protocol for carcinoma of the vulva Authors: Alexander B. Olawaiye, Elliot A. Asare, Ian S. Hagemann, Priya R. Bhosale, Stephanie Gaillard, Brian Rous, Bunja Rungruang, Shitanshu Uppal, Gulisa Turashvili, Kaled M. Alektiar, Jonathan A. Cosin, Uma Krishnamurti, Lee‐may Chen, Keiichi Fujiwara, Matthew A. Powell, Mauricio A. Cuello, David G. Mutch Published: 2026 ABSTRACT AbstractThe American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) staging for all cancer sites has been updated periodically as a published manual for many years. The last update of the manual version, the eighth edition AJCC Cancer Staging Manual, went into use on January 1, 2018. The AJCC has since restructured and updated its processes for curating, analyzing, and publishing updates to the TNM staging system. All AJCC staging‐related data are now housed on its new application programming interface. Consequently, the subsequent AJCC TNM staging updates are now published electronically as protocols and are released by disease sites. The protocol for carcinoma of the vulva, AJCC version 9, is now published. The new TNM vulvar cancer staging was validated using the American College of Surgeons’ National Cancer Data Base. This article highlights the changes to the new AJCC TNM staging protocol for carcinoma of the vulva; these changes align with the 2021 International Federation for Gynecology and Obstetrics staging. The most important of the changes are: (1) a new method for depth of invasion measurement, (2) the addition of a new T subcategory—T4, (3) redefined N subcategories, and (4) an increased number of M subcategories with the addition of clinical to all M subcategories. INTRODUCTION Vulvar cancer represents a relatively rare but significant component of global cancer burden, ranking 29th in incidence worldwide with an estimated 48,894 new cases and 18,868 deaths in 2022. 1 In the United States, approximately 7130 new cases and 1750 deaths are expected in 2026, representing 0.7% of all cancers in women. 2 Similar to other solid cancers, cancer care providers need to have a means to describe the extent of spread and prognosis of vulvar cancer across institutional, national, and international boundaries, and staging fulfils this purpose. STAGING SYSTEMS FOR GYNECOLOGIC CANCERS There are two staging systems for gynecologic cancers used by clinicians for evaluating prognosis and choosing among treatment options: the tumor‐node‐metastasis (TNM) system and the International Federation for Gynecology and Obstetrics (FIGO) system. The TNM system is produced by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer. The AJCC liaises with both FIGO and the International Union Against Cancer in producing its TNM staging. Because of this collaboration, the AJCC TNM staging aligns with FIGO staging, and the only difference is that the AJCC TNM staging includes granular details of each staging component. The FIGO Committee on Women’s Cancer published its most recent update to carcinoma of the vulva in 2021. 3 There was an outstanding collaboration between the AJCC and FIGO during the development of the 2021 FIGO staging for the carcinoma of the vulva. The AJCC facilitated the use of the American College of Surgeons' National Cancer Data Base to derive the staging components, resulting in a validated FIGO staging upon publication. In 2023, the AJCC released version 9 of its vulvar cancer staging protocol, marking a significant evolution in the classification and prognostic assessment of vulvar malignancies. This update reflects advances in tumor biology and imaging and aligns AJCC staging closely with the contemporary FIGO staging. The new protocol aims to improve diagnostic precision, enhance prognostic accuracy, and support more individualized treatment planning. The new protocol went into use on January 1, 2024. The purpose of this article is to provide a high‐level overview of the major changes in version 9 of the AJCC TNM vulvar cancer staging protocol. The previous AJCC TNM staging for carcinoma of the vulva (AJCC Cancer Staging Manual, eighth edition), in alignment with FIGO, derived the stages and substages from literature review of published data, which was understandable because that was how most staging revisions had been done. The problem with that approach was the source data for the publications and the heterogeneity of the analyses done. Most publications on carcinoma of the vulva are from single‐institution or multi‐institutional, retrospective studies. This reduced the prognostication capacity of the staging. The new FIGO revision and the AJCC version 9 protocol for staging carcinoma of the vulva were both created using data from the American College of Surgeons' National Cancer Data Base. All collected characteristics, along with the associated survival data, were fed into a statistical software program. The output grouped together tumor characteristics with overlapping survival data. This resulted in the most evidentially robust gynecologic cancer staging ever created by the FIGO and also by the AJCC (Figures 1 and 2, Tables 1 and 2). Vulvar cancer survival, clinical. Kaplan–Meier curve 2010–2019. Vulvar cancer survival, pathological. Kaplan–Meier curve 2010–2019. TABLE 1Vulvar cancer, clinical: National Cancer Data Base clinical stage grouping 0‐year through 5‐year survival.Clinical stage groupNo. of patients, n = 18,589%Median survival0‐year survival1‐year survival2‐year survival3‐year survival4‐year survival5‐year survivalMonthsLower 95% CI, monthsUpper 95% CI, monthsIA4602100.096.6791.6587.6583.6179.99129.35IB7618100.091.6083.4276.8971.0165.30100.3095.11104.87II2187100.081.9768.1360.0053.8049.8059.6053.2267.48IIIA1189100.079.7665.9558.7052.9348.2955.0046.8562.92IIIB848100.081.3764.3355.9950.1047.5848.4639.6668.73IIIC473100.067.0646.2939.7235.0828.1820.2118.2024.97IVA313100.051.9235.8730.1025.4424.2612.5510.8116.66IVB1359100.045.5230.7824.4021.6719.5010.058.7411.17Abbreviation: CI, confidence interval. Vulvar cancer, clinical: National Cancer Data Base clinical stage grouping 0‐year through 5‐year survival. Abbreviation: CI, confidence interval. TABLE 2Vulvar cancer, pathological: National Cancer Data Base clinical stage grouping 0‐year through 5‐year survival.Pathological stage groupNo. of patients (n = 18,028)%Median survival0‐year survival1‐year survival2‐year survival3‐year survival4‐year survival5‐year survivalMonthsLower 95% CI, monthsUpper 95% CI, monthsIA2297100.098.0595.9293.1189.7085.27129.97IB9772100.095.8989.5384.0079.0173.81123.07118.64II729100.093.3382.0974.1867.4062.3592.4283.25100.67IIIA1089100.089.8275.8968.4561.8657.4874.7467.2585.49IIIB1574100.084.7169.3960.4753.9350.1660.6850.9974.58IIIC1027100.067.4445.8939.2735.1630.1619.8818.2021.91IVA181100.054.9739.8132.2025.7224.9216.3610.8120.76IVB1359100.045.5230.7824.4021.6719.5010.058.7411.17Abbreviation: CI, confidence interval. Vulvar cancer, pathological: National Cancer Data Base clinical stage grouping 0‐year through 5‐year survival. Abbreviation: CI, confidence interval. The new staging cannot be compared head‐to‐head with the previous staging because the new stages and substages are very different from the older version; however, without discordance, the survival curves generated based on the new staging demonstrated an increasingly worse prognosis as the disease stage became higher. GENERAL CHANGES The release of version 9 is part of the AJCC’s broader transition to modular, protocol‐by‐protocol, digital publication, enabling more frequent site‐specific updates as new evidence emerges. This approach ensures that clinicians, pathologists, radiologists, and registrars have access to the most current staging information without waiting for full print edition print cycles. Overall, the updated AJCC vulvar cancer staging protocol represents a meaningful advancement in the classification of vulvar malignancies. By integrating refined anatomic criteria, molecular markers, and modern imaging principles, version 9 supports more accurate staging and improved patient‐centered care. As clinical practice continues to evolve, this framework provides a robust foundation for research, treatment planning, and outcome reporting in vulvar cancer. A major conceptual shift in version 9 is the revised method for measuring depth of invasion, which is now standardized to improve reproducibility and reduce interobserver variability in assessing vulvar squamous cell carcinoma (Figure 3). This change is particularly effective for distinguishing T1a from T1b tumors, categories that carry different prognostic implications and influence surgical decision‐making. 4 , 5 The other implication of this change is that a significant number of tumors previously staged as T1b would now be T1a. This stage migration does not compromise prognosis; rather, it refines it. It may also be protective against overtreatment. The update also introduces a new T4 category, recognizing a subset of tumors with more extensive local invasion that require distinct clinical considerations. Depth of invasion measurement. Depth of invasion is measured from the basement membrane of the deepest, adjacent, dysplastic, tumor‐free rete ridge to the deepest point of invasion (right arrow). The arrow on the left demonstrates the previous method used by the eighth edition of the AJCC Cancer Stating Manual, which measured the depth of invasion from the epithelial‐stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. AJCC indicates American Joint Committee on Cancer. Version 9 incorporates human papillomavirus (HPV) status (for which p16 serves as a surrogate marker) in acknowledgement of the growing evidence that HPV‐associated tumors behave differently, respond more favorably to radiation therapy, and may carry a better prognosis. 6 , 7 , 8 It also incorporates TP53 status: HPV‐independent carcinomas are further divided into TP53‐abnormal and TP53 wide‐type categories. These molecular integrations reflect a broader trend in oncology toward biologically informed staging systems. The new protocol also emphasizes the role of advanced imaging in staging, providing expanded guidance on radiologic assessment of both primary tumors and nodal disease. This aligns with the increasing reliance on three‐dimensional imaging to evaluate perineal lesions, assess local extension, and detect regional lymph node involvement. T CATEGORY CHANGES The only change in the T category is the newly created T4 (Table 3). This describes a tumor fixed to pelvic bone. It is possible to assess for and include this new T category in staging because of the acceptance of three‐dimensional imaging findings as part of vulvar cancer staging. TABLE 3Definition of primary tumor (T).T categoryFIGO stageT criteriaTXPrimary tumor cannot be assessedT0No evidence of primary tumorT1ITumor confined to the vulvaT1aIA Tumor size ≤2 cm in greatest dimension and stromal invasion ≤1 mm Note: Depth of invasion is measured from the basement membrane of the deepest, adjacent, tumor‐free rete ridge to the deepest point of invasion. T1bIB Tumor size >2 cm in greatest dimension or stromal invasion >1 mm Note: Depth of invasion is measured from the basement membrane of the deepest, adjacent, tumor‐free rete ridge to the deepest point of invasion. T2IITumor of any size with extension to lower one third of urethra, lower one third of vagina, lower one third of anusT3IIIATumor of any size with disease extension to upper two thirds of urethra, upper two thirds of vagina, bladder mucosa, rectal mucosaT4IVATumor fixed to pelvic boneAbbreviation: FIGO, International Federation for Gynecology and Obstetrics. Definition of primary tumor (T). Tumor size ≤2 cm in greatest dimension and stromal invasion ≤1 mm Note: Depth of invasion is measured from the basement membrane of the deepest, adjacent, tumor‐free rete ridge to the deepest point of invasion. Tumor size >2 cm in greatest dimension or stromal invasion >1 mm Note: Depth of invasion is measured from the basement membrane of the deepest, adjacent, tumor‐free rete ridge to the deepest point of invasion. Abbreviation: FIGO, International Federation for Gynecology and Obstetrics. N CATEGORY CHANGES This is where most changes were made in the version 9 vulvar cancer protocol compared with the eighth edition AJCC Cancer Staging Manual vulvar cancer chapter (Table 4). N1 previously had two subcategories (N1a and N1b). The new N1 has four subcategories (N1mi, N1a, N1b, and N1c). Lymph node number has been eliminated from N1 category, and the N1 subcategories are based on the size and location of lymph node metastases. There were three N2 subcategories (N2a, N2b, and N2c) in the eighth edition manual vulvar cancer chapter. The new N2 category has only one definition, which is different from the previous N2 definition, and has no N2 subcategories. The N3 category has been eliminated. Nodal reclassification is a significant component of this new revision of vulvar cancer staging in that it has resulted in fewer N subcategories with precise prognostication according to the survival curves. This is one aspect of the old vulvar cancer staging that was not user‐friendly and, frankly, was confusing. TABLE 4Definition of regional lymph nodes (N).N categoryFIGO stageN criteriaNXRegional lymph nodes cannot be assessedN0No regional lymph node metastasisN0(i+)Isolated tumor cells in regional lymph node(s) ≤0.2 mm, or single cells or clusters of cells ≤200 cells in a single lymph node cross‐sectionN1IIITumor involvement of nonfixed, nonulcerated regional lymph nodesN1miIIIATumor involvement >0.2 mm but ≤2.0 mm in greatest dimension of regional lymph nodesN1aIIIATumor involvement >2.0 mm but ≤5.0 mm of regional lymph nodesN1bIIIBTumor involvement >5.0 mm of regional lymph nodesN1cIIICTumor involvement of regional lymph nodes with extranodal extensionN2IVATumor involvement of fixed or ulcerated regional lymph nodesAbbreviation: FIGO, International Federation for Gynecology and Obstetrics. Definition of regional lymph nodes (N). Abbreviation: FIGO, International Federation for Gynecology and Obstetrics. M CATEGORY CHANGES The M category has been modified by including c (clinical) or p (pathological) before the letter M, and there are now three M subcategories (cM0, cM1, and pM1; Table 5). Similar to the T category, this change was made because it is now possible to assess for and include this new cM1 subcategory in staging because of the acceptance of three‐dimensional imaging findings as part of vulvar cancer staging. In future staging revisions for carcinoma of the vulva, robust data from the newly incorporated, three‐dimensional imaging information into staging may lead to important modifications in the M category. TABLE 5Definition of distant metastasis (M).M categoryFIGO stageM criteriacM0No distant metastasiscM1IVBDistant metastasispM1IVBMicroscopic confirmation of distant metastasisAbbreviations: cM, clinical metastasis category; FIGO, International Federation for Gynecology and Obstetrics; pM, pathological metastasis category. Definition of distant metastasis (M). Abbreviations: cM, clinical metastasis category; FIGO, International Federation for Gynecology and Obstetrics; pM, pathological metastasis category. PROGNOSTIC STAGE GROUPING Prognostic stage group is the summary of the combinations of the TNM categories and subcategories (Table 6). For gynecologic cancers, the stage group is usually identical to the FIGO stage for any particular tumor. TABLE 6American Joint Committee on Cancer prognostic stage grouping.When T is…And N is…And M is…Then the stage group is…T1N0M0IT1aN0M0IAT1bN0M0IBT2N0M0IITX–T3N1M0IIIT3N0M0IIIATX–T3N1mi, N1aM0IIIATX–T3N1bM0IIIBTX–T3N1cM0IIICT4Any NM0IVAAny TN2M0IVAAny TAny NM1IVBAbbreviations: M, metastasis category; N, node category; T, tumor category; X, cannot be assessed. American Joint Committee on Cancer prognostic stage grouping. Abbreviations: M, metastasis category; N, node category; T, tumor category; X, cannot be assessed. CONCLUSIONS The version 9 AJCC TNM staging protocol for carcinoma of the vulva is user‐friendly and incorporates several changes that undoubtedly would improve the clinical and research utilities of vulvar cancer staging. Furthermore, it permits the use of three‐dimensional imaging but also allows for vulvar cancer staging when such a resource is not available. Therefore, the staging can be performed across all world regions. CONFLICT OF INTEREST STATEMENT Stephanie Gaillard reports personal/consulting fees from AstraZeneca, Corcept Therapeutics, Organon, and Orion Corporation; service on a Data and Safety Monitoring Committee for TOR BioTherapeutics; and a patent licensed by Sermonix outside the submitted work. Gulisa Turashvilli reports personal/consulting fees from AbbVie and AstraZeneca outside the submitted work. Lee‐may Chen reports institutional grants/contracts for Gynecologic Oncology Group clinical trials; payment from UpToDate as a contributor; and service as an American ACOG liaison to the American College of Surgeons Board of Governors outside the submitted work. Matthew A. Powell reports personal/consulting fees from AstraZeneca, EISAI Inc., GlaxoSmithKline, and Merck outside the submitted work. The remaining authors disclosed no conflicts of interest.